New engineered immune cell therapy enters human testing for tough digestive cancers
Disease control
Ongoing
This is an early-stage study testing the safety and optimal dose of a new treatment called LB1908, a type of CAR-T cell therapy, for adults with advanced cancers of the stomach, esophagus, or pancreas. The therapy involves collecting a patient's own immune cells, engineering them…
Phase: PHASE1 • Sponsor: Legend Biotech USA Inc • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC